LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
Condition: Hypertension
MeSH terms: Hypertension
Intervention: losartan potassium; Comparator: carvedilol; Comparator: losartan (+) hydrochlorothiazide (HCTZ); Comparator: carvedilol (+) hydrochlorothiazide
Intervention description: Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan); Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan); Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan); Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Intervention MeSH terms: Losartan; Hydrochlorothiazide; Carvedilol
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 201.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The primary objective of this study is to evaluate efficacy, arterial stiffness measured by
      Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24
      weeks of treatment in patients with the essential hypertension.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female adults, 18 years or over

          -  Essential Hypertension with mean SBP (systolic blood pressure) ≥ 140 mm Hg or mean DBP
             (diastolic blood pressure) ≥ 90 mm Hg* when blood pressure is measured at Visit 1(week
             -2) and at Visit 2(week 0).

        If diabetes patients, mean SBP ≥ 130 mm Hg or mean DBP ≥ 80 mm Hg (Mean of blood pressure
        values measured consecutively at least 2 minutes apart)

          -  Patient who is willing to, and is able to sign the informed consent form

        Exclusion Criteria:

          -  Patient Is Pregnant Or Breastfeeding, Or Expecting To Conceive Within The Projected
             Duration Of The Study

          -  Patient Has Known Or Suspected Secondary Hypertension Of Any Etiology

          -  Patient has history of malignant hypertension

          -  Patient has history of cerebrovascular accident (cerebral infarction) or myocardiac
             infarction within the last 6 months

          -  Patient takes antihypertensive drugs